VOLGA –a super speciality division with focus on Urology & Nephrology ailments has been launched in the year 2016.
The focussed sub-therapies in Urology are anti-BPH (Benign Prostatic Hyperplasia), OAB (Over Active Bladder), ED (Erectile Dysfunction), CaP (Cancer of Prostate) & Renal Calculi. The team has launched select 9 brands as therapeutic offerings for the Urologists.
The initial focus in Nephrology segment is anaemia caused due to CKD. Team has launched Biosimilar Darbepoetin Alfa to the Nephrologists.
With the ageing population estimated to only grow & the complexities of disease management to increase, team VOLGA would work on comprehensive services to the doctors, patient, care givers & partners.
With an aim to offer value addition to all the stakeholders & a vibrant new team, VOLGA is poised to gain significant mind share & market share in the years to come.